{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447931211
| IUPAC_name = Ethyl 7-chloro-4-oxo-5-phenyl-2,3-dihydro-1,5-benzodiazepine-1-carboxylate
| image = Arfendazam.svg
| width = 180

<!--Clinical data-->
| tradename =  
| legal_status =  

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 37669-57-1
| ATC_prefix = none
| PubChem = 65803
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 2104444
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 59219
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = P37G7BTX8V

<!--Chemical data-->
| C=18 | H=17 | Cl=1 | N=2 | O=3 
| molecular_weight = 344.792
| smiles = ClC1=CC2=C(C=C1)N(CCC(N2C3=CC=CC=C3)=O)C(OCC)=O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H17ClN2O3/c1-2-24-18(23)20-11-10-17(22)21(14-6-4-3-5-7-14)16-12-13(19)8-9-15(16)20/h3-9,12H,2,10-11H2,1H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = NXJWVCHVPUCWJS-UHFFFAOYSA-N
}}

'''Arfendazam''' ([[International Nonproprietary Name|INN]])<ref>{{cite web|title=International Nonproprietary Names for Pharmaceutical Substances. Proposed International Nonproprietary Names (Prop. INN): List 39. Supplement to WHO Chronicle, 1978, Vol. 32, No. 3 (March)|url=http://www.who.int/medicines/publications/druginformation/innlists/PL39.pdf|publisher=World Health Organization|accessdate=4 December 2015|page=3}}</ref> is a drug which is a [[benzodiazepine]] derivative. Arfendazam is a 1,5-benzodiazepine, with the nitrogen atoms located at positions 1 and 5 of the diazepine ring, and so is most closely related to other 1,5-benzodiazepines such as [[clobazam]]. 

Arfendazam has [[sedative]] and [[anxiolytic]] effects similar to those produced by other benzodiazepine derivatives, but is a [[partial agonist]] at [[GABAA receptor|GABA<sub>A</sub>]] receptors, so the sedative effects are relatively mild and it produces [[muscle relaxant]] effects only at very high doses.<ref>Müller E. Benzodiazepine receptor interactions of arfendazam, a novel 1, 5-benzodiazepine. ''Pharmacopsychiatry'' 1985, (18):10-11.</ref><ref>Müller WE, Groh B, Bub O. In vitro and in vivo studies of the mechanism of action of arfendazam, a novel 1, 5-benzodiazepine. ''Pharmacopsychiatry'' 1986, (10):314-315.</ref> 

Arfendazam produces an active [[metabolite]] [[lofendazam]], which is thought to be responsible for part of its effects.<ref>J. Adrien, F. Albani, A. Baruzzi, M. Berger, E.O. Bixler, A.A. Borbeley, D.G. Dikeos, R. Drucker-Colin, R. Fritsch Montero, Y. Hishikawa, S. Inoue, A. Kales, E. Lugaresi, H. Merchant-Nancy, J.M. Monti. ''The Pharmacology of Sleep''. Springer. {{ISBN|978-3-540-58961-7}}</ref>

{{sedative-stub}}

==See also==
*[[Benzodiazepine]]

==References==
{{Reflist|2}}

{{Sedatives}}
{{Anxiolytics}}
{{Benzodiazepines}}
{{GABAA PAMs}}

[[Category:Benzodiazepines]]
[[Category:Carbamates]]
[[Category:Chloroarenes]]
[[Category:GABAA receptor positive allosteric modulators]]
[[Category:Lactams]]

{{sedative-stub}}